About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 373781, 8 pages
http://dx.doi.org/10.1155/2011/373781
Research Article

The Effects of Erythropoietin Dose Titration during High-Fat Diet-Induced Obesity

Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Received 16 September 2010; Revised 24 January 2011; Accepted 3 February 2011

Academic Editor: Oreste Gualillo

Copyright © 2011 Amanda Foskett et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Yach, D. Stuckler, and K. D. Brownell, “Epidemiologic and economic consequences of the global epidemics of obesity and diabetes,” Nature Medicine, vol. 12, no. 1, pp. 62–66, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. G. S. Hotamisligil, “Inflammation and metabolic disorders,” Nature, vol. 444, no. 7121, pp. 860–867, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. S. Schenk, M. Saberi, and J. M. Olefsky, “Insulin sensitivity: modulation by nutrients and inflammation,” Journal of Clinical Investigation, vol. 118, no. 9, pp. 2992–3002, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. V. Z. Rocha and P. Libby, “Obesity, inflammation, and atherosclerosis,” Nature reviews. Cardiology, vol. 6, no. 6, pp. 399–409, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. L. A. Szczech, H. X. Barnhart, S. Sapp et al., “A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment,” Kidney International, vol. 77, no. 3, pp. 239–246, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. K. Singh, L. Szczech, K. L. Tang et al., “Correction of anemia with epoetin alfa in chronic kidney disease,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2085–2098, 2006. View at Publisher · View at Google Scholar · View at PubMed
  8. G. L. Semenza, S. T. Koury, M. K. Nejfelt, J. D. Gearhart, and S. E. Antonarakis, “Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 19, pp. 8725–8729, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. G. L. Semenza, “Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis,” Blood, vol. 114, no. 10, pp. 2015–2019, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. E. B. Rankin, M. P. Biju, Q. Liu et al., “Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo,” Journal of Clinical Investigation, vol. 117, no. 4, pp. 1068–1077, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. Pelletier, S. Gingras, M. Funakoshi-Tago, S. Howell, and J. N. Ihle, “Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function,” Molecular and Cellular Biology, vol. 26, no. 22, pp. 8527–8538, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. N. Kertesz, J. Wu, T. H.-P. Chen, H. M. Sucov, and H. Wu, “The role of erythropoietin in regulating angiogenesis,” Developmental Biology, vol. 276, no. 1, pp. 101–110, 2004. View at Publisher · View at Google Scholar · View at PubMed
  13. H. Wu, S. H. Lee, J. Gao, X. Liu, and M. L. Iruela-Arispe, “Inactivation of erythropoietin leads to defects in cardiac morphogenesis,” Development, vol. 126, no. 16, pp. 3597–3605, 1999. View at Scopus
  14. X. Yu, J. J. Shacka, J. B. Eells et al., “Erythropoietin receptor signalling is required for normal brain development,” Development, vol. 129, no. 2, pp. 505–516, 2002. View at Scopus
  15. C. J. Parsa, A. Matsumoto, J. Kim et al., “A novel protective effect of erythropoietin in the infarcted heart,” Journal of Clinical Investigation, vol. 112, no. 7, pp. 999–1007, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Sakanaka, T. C. Wen, S. Matsuda et al., “In vivo evidence that erythropoietin protects neurons from ischemic damage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 8, pp. 4635–4640, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Bernaudin, H. H. Marti, S. Roussel et al., “A potential role for erythropoietin in focal permanent cerebral ischemia in mice,” Journal of Cerebral Blood Flow and Metabolism, vol. 19, no. 6, pp. 643–651, 1999. View at Scopus
  18. P. Hojman, C. Brolin, H. Gissel et al., “Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles,” PLoS One, vol. 4, no. 6, Article ID e5894, 2009. View at Publisher · View at Google Scholar · View at PubMed
  19. O. Katz, M. Stuible, N. Golishevski et al., “Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models,” Journal of Endocrinology, vol. 205, no. 1, pp. 87–95, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. J. R. Wright, Y. C. Ung, J. A. Julian et al., “Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia,” Journal of Clinical Oncology, vol. 25, no. 9, pp. 1027–1032, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. D. Rizzo, M. Brouwers, P. Hurley et al., “American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer,” Blood, vol. 116, no. 20, pp. 4045–4059, 2010. View at Publisher · View at Google Scholar · View at PubMed
  22. M. Ogilvie, X. Yu, V. Nicolas-Metral et al., “Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts,” Journal of Biological Chemistry, vol. 275, no. 50, pp. 39754–39761, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. T. Petruschke and H. Hauner, “Tumor necrosis factor-α prevents the differentiation of human adipocyte precursor cells and causes delipidation of newly developed fat cells,” Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 3, pp. 742–747, 1993. View at Publisher · View at Google Scholar · View at Scopus
  24. X. Chen, K. Xun, L. Chen, and Y. Wang, “TNF-α, a potent lipid metabolism regulator,” Cell Biochemistry and Function, vol. 27, no. 7, pp. 407–416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. G. Netea, L. A. B. Joosten, E. Lewis et al., “Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance,” Nature Medicine, vol. 12, no. 6, pp. 650–656, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. E. P. Zorrilla, M. Sanchez-Alavez, S. Sugama et al., “Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 26, pp. 11097–11102, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. N. Seubert, Y. Royer, J. Staerk et al., “Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer,” Molecular Cell, vol. 12, no. 5, pp. 1239–1250, 2003. View at Publisher · View at Google Scholar · View at Scopus